Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 45–46

HOS-109544 · Präparat HOS-093201

45 Other Non-Nucleoside Reverse Not studied clinically. In vitro Careful monitoring for any Transcriptase Inhibitors studies show that the metabolism occurrence of drug toxicity (NNRTIs) (including but not of voriconazole may be inhibited and/or lack of efficacy, and dose limited to: delavirdine, by NNRTIs and voriconazole may adjustment may be needed. nevirapine)* inhibit the metabolism of NNRTIs. [CYP3A4 substrates, inhibitors The findings of the effect of or CYP450 inducers] efavirenz on voriconazole suggest that the metabolism of voriconazole may be induced by an NNRTI. Antipsychotics Lurasidone Although not studied, Contraindicated (see section [CYP3A4 substrate] voriconazole is likely to 4.3) significantly increase the plasma concentrations of lurasidone. Pimozide Although not studied, increased Contraindicated (see section [CYP3A4 substrate] plasma concentrations of pimozide 4.3) can lead to QTc prolongation and rare occurrences of torsades de pointes. Anti virals Letermovir Voriconazole Cmax ↓ 39% If concomitant administration of [CYP2C9 and CYP2C19 Voriconazole AUC0-12 ↓ 44% voriconazole with letermovir inducer] Voriconazole C12 ↓ 51% cannot be avoided, monitor for loss of voriconazole effectiveness. Benzodiazepines [CYP3A4 substrates] Dose reduction of Midazolam (0.05 mg/kg IV In an independent published study, benzodiazepines should be single dose) Midazolam AUC0-  3.7-fold considered.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): letermovir (HOS-090621) lead (HOS-085592) pimozide (HOS-085600) efavirenz (HOS-087947) delavirdine (HOS-109468) nevirapine (HOS-088064) lurasidone (HOS-086148) midazolam (HOS-086167)